A Food and Drug Administration (FDA) expert panel has reignited a debate over whether hormone therapy should be used to treat ...

The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and the U.K. have already cleared it for use.

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who ...

Bypassing its standard pathways for scientific discussions, FDA has recently held a slew of so-called "expert panels" that ...

The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...

Hone Health reports that the controversial 2002 WHI study misled menopause care, linking HRT to breast cancer and causing ...

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program. Dr.

FDA Commissioner Marty Makary, MD, MPH, announced that George Tidmarsh, MD, PhD, a cancer and pediatric specialist, will ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

The PMCPA ruled that “a systemic failure in compliance oversight” at Theramex has brou | The PMCPA ruled that “a systemic ...

Combination therapy screening is the process of testing multiple drugs together to see how they interact. The goal is to find ...